Novacyt S.A.
Half Year Update
Regulatory News:
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) ("Novacyt", the "Company" or the “Group”), an international specialist in clinical diagnostics, announces a half year update in advance of its investor meeting today.
Six months revenue ended 30 June 2021
£'000 |
H1 2021 |
H1 2020 |
YoY Growth |
YoY Growth |
|
|
|
Actual |
% |
Total Group Revenue |
94,710 |
63,252 |
31,458 |
50% |
|
|
|
|
|
DHSC Revenue |
40,759 |
18,406 |
22,353 |
121% |
|
|
|
|
|
Non-DHSC Revenue |
53,951 |
44,846 |
9,105 |
20% |
Unaudited revenue for the first half of 2021 increased over 50% to £94.7 million, compared to £63.3 million for the first half of 2020. Of this total revenue, £54 million came from a mixture of overseas sales and a growing UK private testing market, leading to non-DHSC revenue growing 20% year-on-year.
As announced on 21 May 2021, the DHSC sales of £40.8 million are in dispute.
Lesen Sie auch
Business update
Contract award with DHSC under PHE framework
Primerdesign, a wholly owned subsidiary of Novacyt, has been awarded a new contract under the PHE National Microbiology Framework,
effective immediately, for the supply of PROmate COVID-19 tests to the NHS. The PROmate COVID-19 tests have been developed to run on the Company’s q16 and q32 PCR instrument platforms. The q16 and
q32 near patient PCR instrument platforms using the PROmate COVID-19 test have been validated and can be used at select NHS hospitals. The contract is valued at up to £4.7m and will last until 31
March 2022. There are no minimum purchase levels as part of this contract.